BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32641077)

  • 1. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
    Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
    Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
    Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
    Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
    Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
    Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
    Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
    Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
    Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
    Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
    Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
    J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
    Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
    PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
    Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
    Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
    Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
    J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance.
    Zhou J; Zhu X; Wu S; Guo J; Zhang K; Xu C; Chen H; Jin Y; Sun Y; Zheng S; Chen Y
    Cancer Biol Med; 2020 Feb; 17(1):169-180. PubMed ID: 32296584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.